ClinicalTrials.gg
CompletedNCT03406260Updated Dec 2, 2019Results posted

A Study of Lasmiditan in Healthy Elderly Participants

A Phase 1 interventional study of Lasmiditan and Placebo in Healthy, sponsored by Eli Lilly and Company. Completed at 2 sites in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-02.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

The purposes of this study are to evaluate the effect of lasmiditan on blood pressure, as well as to look at the amount of study drug that gets into the blood stream and how long it takes the body to get rid of it in healthy elderly participants. The tolerability of the study drug will also be evaluated. Information about any side effects that may occur will also be collected. This study will take about 11 days, not including screening. Screening is required within 28 days prior to the start of the study.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.

Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy males or females, as determined through medical history and physical examination
  • Have a (BMI) of 19.0 to 35.0 kilograms per meter squared (kg/m²), inclusive, at the time of screening.

Exclusion criteria

Exclusion Criteria:

  • Have known allergies to lasmiditan, related compounds, or any components of the formulation.
  • Are persons who have previously received lasmiditan.
  • Have a history of, or (ECG) findings of, bradycardia, heart block, tachy or brady arrhythmias, or have any other abnormality in the 12-lead ECG that, in the opinion of the investigator, increases the risks associated with participating in the study.
  • Have significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data. appendectomy, splenectomy, and cholecystectomy are considered as acceptable.
  • Show a history of central nervous system (CNS) conditions such as strokes, , significant head trauma, seizures, CNS infections, migraines, brain surgery, or any other neurological conditions that, in the opinion of the investigator, increase the risk of participating in the study.
  • Show evidence of active renal disease (e.g. diabetic renal disease, polycystic kidney disease) or estimated \<60 milliliters per minute per 1.73 meter squared (mL/min/m²).
  • Have a history of syncope, presyncopy, uncontrolled vertigo, postural dizziness, or at risk for falls, as judged to be clinically significant by the investigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Lasmiditan 200 mg (milligrams)

    Participants received 200 mg of Lasmiditan tablet orally in the fasted state with approximately 240 (milliliter) mL of room temperature water in the morning of Days 1, 3, and 5, while participants were in a sitting position.

    Drug: Lasmiditan

  • Experimental
    Lasmiditan 100 mg

    Participants received 100 mg of Lasmiditan tablet orally in the fasted state with approximately 240 mL of room temperature water in the morning of Days 1, 3, and 5, while participants were in a sitting position.

    Drug: Lasmiditan

  • Placebo comparator
    Placebo

    Participants received placebo tablet orally in the fasted state with approximately 240 mL of room temperature water in the morning of Days 1, 3, and 5, while participants were in a sitting position.

    Drug: Placebo

Interventions

  • Administered orally.

    Also known as: LY573144

  • DrugPlacebo

    Administered orally.

06

What researchers measure

Primary outcomes

  1. Pharmacodynamics: Change From Baseline in Peak Hourly Mean Values of Systolic Blood Pressure (SBP)

    Mean 24-hour systolic blood pressure (SBP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using linear mixed effects model adjusting for baseline, treatment, treatment sequence, period, treatment by time point interaction, and a random effect of participant.

    Time frame: Baseline through 24 hours after each administration of study drug

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lasmiditan

    Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lasmiditan.

    Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours, postdose

  2. PK: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Lasmiditan

    PK: Area under the Concentration Versus Time Curve from Zero to Infinity (AUC\[0-∞\]) of Lasmiditan.

    Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours, postdose

07

Results

Posted Dec 2, 2019

Participant flow

Period 1
Participant flow — Period 1
MilestoneSequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6
Started666666
Received at least 1 dose of study drug666666
Completed666656
Not completed000010
Withdrew: Adverse event000010
Period 2
Participant flow — Period 2
MilestoneSequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6
Started666656
Completed666656
Not completed000000
Period 3
Participant flow — Period 3
MilestoneSequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6
Started666656
Completed666656
Not completed000000

Outcome measures

PrimaryPharmacodynamics: Change From Baseline in Peak Hourly Mean Values of Systolic Blood Pressure (SBP)

Mean 24-hour systolic blood pressure (SBP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using linear mixed effects model adjusting for baseline, treatment, treatment sequence, period, treatment by time point interaction, and a random effect of participant.

Time frame:
Baseline through 24 hours after each administration of study drug
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Pharmacodynamics: Change From Baseline in Peak Hourly Mean Values of Systolic Blood Pressure (SBP)
millimeters of mercury (mmHg)Lasmiditan 200 mgLasmiditan 100 mgPlacebo
Pharmacodynamics: Change From Baseline in Peak Hourly Mean Values of Systolic Blood Pressure (SBP)15.79 ± 1.77415.50 ± 1.82017.14 ± 1.797
Statistical analysis
  • Lasmiditan 100 mg vs Placebo · Linear Mixed Effects Model · p = <0.0001 · Ls mean difference (final vaules): -1.63 · 95% CI -1000 to 1.81
  • Lasmiditan 200 mg vs Placebo · Linear Mixed Effects Model · p = <0.0001 · Ls mean difference (final vaules): -1.35 · 95% CI -1000 to 2.06
SecondaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Lasmiditan

Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lasmiditan.

Time frame:
Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours, postdose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lasmiditan
nanogram per milliliter (ng/mL)Lasmiditan 100 mgLasmiditan 200 mg
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lasmiditan159 ± 32339 ± 34
SecondaryPK: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Lasmiditan

PK: Area under the Concentration Versus Time Curve from Zero to Infinity (AUC\[0-∞\]) of Lasmiditan.

Time frame:
Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours, postdose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*h/mL)
PK: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Lasmiditan
nanogram*hour per milliliter (ng*h/mL)Lasmiditan 100 mgLasmiditan 200 mg
PK: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Lasmiditan1170 ± 342470 ± 35

Adverse events

Collected over Up To 12 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lasmiditan 200 mg0/36 (0%)0/36 (0%)15/36 (41.7%)
Lasmiditan 100 mg0/35 (0%)0/35 (0%)6/35 (17.1%)
Placebo0/35 (0%)0/35 (0%)0/35 (0%)
Most frequent other events
Most frequent other events
EventLasmiditan 200 mgLasmiditan 100 mgPlacebo
DizzinessNervous system disorders9/365/350/35
FatigueGeneral disorders4/362/350/35
ParaesthesiaNervous system disorders3/363/350/35
HeadacheNervous system disorders2/361/350/35
AnxietyPsychiatric disorders2/360/350/35

Baseline characteristics

All randomized participants who received at least one dose of study drug.

Age, Categorical
Age, Categorical(Participants)Sequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6Total
<=18 years0000000
Between 18 and 65 years1100002
>=65 years55666634
Sex: Female, Male
Sex: Female, Male(Participants)Sequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6Total
Female22232415
Male44434221
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6Total
Hispanic or Latino0101103
Not Hispanic or Latino65655633
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6Total
American Indian or Alaska Native0000000
Asian0000000
Native Hawaiian or Other Pacific Islander0000000
Black or African American1000012
White56666534
More than one race0000000
Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(Participants)Sequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6Total
United States66666636
08

Study locations

2 sites
  • Covance Clinical Research Inc
    Daytona Beach, Florida 32117, United States
  • Covance Clinical Research Inc
    Madison, Wisconsin 53704, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Apr 2018, 2 months.

Results were first posted in Dec 2019, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2018
First posted
Jan 23, 2018
StartActual
Jan 25, 2018
Primary completionActual
Apr 13, 2018
CompletionActual
Apr 13, 2018
Results first posted
Dec 2, 2019
Last update
Dec 2, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03406260
Responsible party
Sponsor
First posted
Jan 23, 2018
Start date
Jan 25, 2018
Primary completion
Apr 13, 2018
Completion
Apr 13, 2018
Results posted
Dec 2, 2019
Last update
Dec 2, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lasmiditan

Start the discussion